Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion clinical trials

Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC pilot study

This study is looking at a new way to treat liver cancer (hepatocellular carcinoma) when previous immune treatments haven't worked. It combines two existing medicines, Avastin and Tecentriq, with something called Fecal Microbiota Transplant (FMT) to see if it helps patients and if it's safe.